These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18502602)

  • 1. [General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
    Mouly S; Charlemagne A; Le Jeunne P; Fagnani F
    Presse Med; 2008 Oct; 37(10):1397-406. PubMed ID: 18502602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic management of uncomplicated gastroesophageal reflux disease in france in 2005: Potential cost savings of omeprazole substitution.
    Mouly S; Charlemagne A; Lejeunne P; Fagnani F
    Curr Ther Res Clin Exp; 2009 Aug; 70(4):282-98. PubMed ID: 24683238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
    van Hout BA; Klok RM; Brouwers JR; Postma MJ
    Clin Ther; 2003 Feb; 25(2):635-46. PubMed ID: 12749518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
    Kivioja A; Linnosmaa I; Vehviläinen A; Vohlonen I
    Eur J Pharm Sci; 2004 Feb; 21(2-3):171-8. PubMed ID: 14757488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
    Remák E; Brown RE; Yuen C; Robinson A
    Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of actual costs in long-term therapy of reflux disease. Use of pantoprazole counts].
    MMW Fortschr Med; 2008 Oct; 150(40):52-3. PubMed ID: 18990887
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
    Zheng RN
    World J Gastroenterol; 2009 Feb; 15(8):990-5. PubMed ID: 19248200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
    Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
    Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of gastric acid-induced illnesses in general practice. The first pantoprazole generic drug has arrived].
    MMW Fortschr Med; 2009 Jan; 151(5):46-7. PubMed ID: 19391415
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.
    Hughes DA; Bodger K; Bytzer P; de Herdt D; Dubois D
    Pharmacoeconomics; 2005; 23(10):1031-41. PubMed ID: 16235976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [All proton pump inhibitors are equally efficacious in standard dosages].
    Hellström PM; Vitols S
    Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
    Kromer W; Horbach S; Lühmann R
    Pharmacology; 1999 Aug; 59(2):57-77. PubMed ID: 10450061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
    Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
    World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
    Lu B; Zhang L; Wang J; Wang B; Zou X; Fei G; Chen D; Wang X; Wu B; Zou D
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1722-1727. PubMed ID: 29575167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.